Catalyst Dossier · compiled by CeliA 🧫

Seagen Inc. (SGEN)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-31 (est.)Phase 2 · brentuximab vedotinimp 7/10
2026-12-31 (est.)Phase 3 · brentuximab vedotinimp 9/10
2027-01-29 (est.)Phase 3 · gemcitabineimp 9/10

Pipeline

Asset	Phase	Indication
Adcetris	Approved	Hodgkin Lymphoma
Tukysa	Phase 2	HER2+ Breast Cancer
SGN-40	Phase 2	Lymphoma, Large B-Cell, Diffuse
SGN-30 (monoclonal antibody)	Phase 2	Hodgkin Disease
SGN-15 (cBR96-doxorubicin immunoconjugate)	Phase 2	Prostatic Neoplasms
Trastuzumab	Phase 3	Metastatic Colorectal Adenocarcinoma
bendamustine	Phase 2	Hodgkin Disease
SGN-15	Phase 2	Carcinoma, Non-Small-Cell Lung
SGN-30 (anti-CD30 mAb)	Phase 2	Anaplastic Large-Cell Lymphoma
SEA-CD40	Phase 2	Melanoma
tucatinib	Phase 3	Gastric Adenocarcinoma
dacarbazine	Phase 2	Hodgkin Disease
nivolumab	Phase 2	Hodgkin Lymphoma
Tisotumab Vedotin (HuMax-TF-ADC)	Phase 2	Ovary Cancer
SGN-40 (anti-huCD40 mAb)	Phase 2	Leukemia, Lymphocytic, Chronic
Lintuzumab (SGN-33)	Phase 2	Acute Myeloid Leukemia
ladiratuzumab vedotin	Phase 2	Triple Negative Breast Neoplasms
SGN-15, Docetaxel	Phase 2	Non-Small Cell Lung Carcinoma
tisotumab vedotin	Phase 2	Ovarian Cancer
doxorubicin	Phase 3	Anaplastic Large-Cell Lymphoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.